Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction : the randomized MARLINA-T2D trial

Show full item record



Permalink

http://hdl.handle.net/10138/227961

Citation

Groop , P-H , Cooper , M E , Perkovic , V , Hocher , B , Kanasaki , K , Haneda , M , Schernthaner , G , Sharma , K , Stanton , R C , Toto , R , Cescutti , J , Gordat , M , Meinicke , T , Koitka-Weber , A , Thiemann , S & von Eynatten , M 2017 , ' Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction : the randomized MARLINA-T2D trial ' , Diabetes, obesity and metabolism , vol. 19 , no. 11 , pp. 1610-1619 . https://doi.org/10.1111/dom.13041

Title: Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction : the randomized MARLINA-T2D trial
Author: Groop, Per-Henrik; Cooper, Mark E.; Perkovic, Vlado; Hocher, Berthold; Kanasaki, Keizo; Haneda, Masakazu; Schernthaner, Guntram; Sharma, Kumar; Stanton, Robert C.; Toto, Robert; Cescutti, Jessica; Gordat, Maud; Meinicke, Thomas; Koitka-Weber, Audrey; Thiemann, Sandra; von Eynatten, Maximilian
Contributor: University of Helsinki, Clinicum
Date: 2017-11
Language: eng
Number of pages: 10
Belongs to series: Diabetes, obesity and metabolism
ISSN: 1462-8902
URI: http://hdl.handle.net/10138/227961
Abstract: Aims: The MARLINA-T2D study (ClinicalTrials. gov, NCT01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to standard-of-care in individuals with type 2 diabetes and albuminuria. Methods: A total of 360 individuals with type 2 diabetes, HbA1c 6.5% to 10.0% (48-86 mmol/ mol), estimated glomerular filtration rate (eGFR) >= 30 mL/min/1.73 m(2) and urinary albumin-tocreatinine ratio (UACR) 30-3000 mg/g despite single agent renin-angiotensin-system blockade were randomized to double-blind linagliptin (n = 182) or placebo (n = 178) for 24 weeks. The primary and key secondary endpoints were change from baseline in HbA1c at week 24 and time-weighted average of percentage change from baseline in UACR over 24 weeks, respectively. Results: Baseline mean HbA1c and geometric mean (gMean) UACR were 7.8% +/- 0.9% (62.2 +/- 9.6 mmol/mol) and 126 mg/g, respectively; 73.7% and 20.3% of participants had microalbuminuria or macroalbuminuria, respectively. After 24 weeks, the placebo-adjusted mean change in HbA1c from baseline was -0.60% (-6.6 mmol/mol) (95% confidence interval [CI], -0.78 to -0.43 [-8.5 to -4.7 mmol/mol]; P Conclusions: In individuals at early stages of diabetic kidney disease, linagliptin significantly improved glycaemic control but did not significantly lower albuminuria. There was no significant change in placebo-adjusted eGFR. Detection of clinically relevant renal effects of linagliptin may require longer treatment, as its main experimental effects in animal studies have been to reduce interstitial fibrosis rather than alter glomerular haemodynamics.
Subject: antidiabetic drug
clinical trial
diabetic nephropathy
DPP-IV inhibitor
glycaemic control
linagliptin
DPP-4 INHIBITOR
MEDICATIONS
ADHERENCE
SAFETY
OMARIGLIPTIN
MONOTHERAPY
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Groop_et_al_201 ... Obesity_and_Metabolism.pdf 861.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record